Intravenous (IV) Ibuprofen Market Statistics 2030:
The global intravenous (IV) ibuprofen market size was valued at $5.34 million in 2020, and is projected to reach $15.48 million by 2030, registering a CAGR of 13.4% from 2021 to 2030. The ibuprofen belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Ibuprofen acts by non-selective inhibition of cyclooxygenase (COX), which is required for the synthesis of prostaglandins through the arachidonic acid pathway. Thus, ibuprofen blocks the synthesis of prostaglandins (PG), which is responsible for inflammation. The intravenous (IV) ibuprofen alone or with combination with other analgesics is used to treat mild to severe pain. NSAIDs, such as ibuprofen are suitably used for children and adults. However, it is not recommended for geriatric population, as there is a risk of ulcers and bleeding in gastrointestinal track (GIT).
The growth of the global intravenous (IV) ibuprofen market is majorly driven by increase in prevalence of arthritis, cardiovascular diseases, and cancer. The various cancers, such as osteosarcoma (bone cancer), nerve cancer, and leukemia cause mild to severe pain. For instance, as per the American Cancer Society (ACS), about 3,910 new cases of bone cancers were diagnosed in U.S in 2021. Furthermore, high bio-availability and rapid analgesic action of ibuprofen are expected to fuel their adoption during the forecast period.
Furthermore, increase in prevalence of bone and muscle disorders, such as ankylosing spondylitis (a rare type of arthritis) and rheumatoid arthritis contributes in the growth of the market. For instance, according to a report from the Journal of Rheumatology, titled ‘Prevalence of ankylosing spondylitis in Spain’, about 7.3% population showed positive screening for ankylosing spondylitis in 2020. In addition, rise in number of orthopedic hospitals and diagnostic centers boosts the diagnosis and treatment of diseases. For instance, according to Definitive Healthcare Organization, there were more than 30,500 orthopedic surgeons in the U.S. in 2020. Thus, increase in prevalence of orthopedic surgery and surge the need for intravenous ibuprofen drive the growth of the IV ibuprofen market.
In addition, increase in prevalence of mucoskeletal diseases contributes in the growth of intravenous (IV) ibuprofen market. According to World Health Organization (WHO), approximately 1.71 billion population suffer from musculoskeletal conditions across the globe. Furthermore, easy availability of ibuprofen as an over the counter medication contributes in growth of market.
Increase in number of product approvals and government regulations for NSAIDs drug boosts the growth of the intravenous (IV) ibuprofen market. For instance, in December 2020, US food and drug administration (FDA) announced the published list of NSAIDs available by prescription and over-the-counter (OTC). It includes, ibuprofen, naproxen, diclofenac, and celecoxib while Ibuprofen and naproxen are also available OTC at lower strengths.
In addition, the U.S. food and drug administration (FDA) approved intravenous (IV) ibuprofen injection for pediatric use at definite doses. The increase in use of ibuprofen injection in children boosts the demand for intravenous (IV) ibuprofen injections. Thus, increase in pediatric population drives the growth of the market. For instance, the State of Americas Children 2021, reported that almost 22% population in the U.S. were children.
Moreover, development in intravenous ibuprofen formulations in the global intravenous (IV) ibuprofen market are anticipated to contribute toward the growth of the market. For instance, in November 2021, Cumberland Pharmaceuticals, a global leader in developing, manufacturing, and marketing a broad range of innovative pharmaceutical products, announced the U.S. Food and Drug Administration (FDA) approval for its caldolor, which is an intravenous ibuprofen used for pre-operative administration. However, side effects associated with ibuprofen impede the growth of the market.
Global Intravenous (IV) Ibuprofen Market Segmentation
The intravenous IV ibuprofen market is segmented on the basis of indication, age group, and region. By indication, the market is categorized into pain/inflammatory and fever. Depending on age group, it is fragmented into pediatrics and adults. By region, the market is analyzed across Australia, Canada, South Korea, China, U.S.
By Age Group
Adults segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Segment Review
Depending on indication, the pain/inflammatory segment dominated the IV ibuprofen market in 2020, and this trend is expected to continue during the forecast period, owing to rise in prevalence of mucoskelatal diseases. However, the fever segment is expected to witness considerable growth during the forecast period, due to prevalence of inflammatory diseases.
On the basis of age group, the adults segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of rare diseases in adults and rise in sedentary lifestyle by adult. However, the pediatrics segment is expected to witness considerable growth during the forecast period, due to increase in pediatric population.
By Indication
Pain segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Depending on the region, U.S. garnered the major share in the intravenous (IV) ibuprofen market in 2020, and is expected to dominate the global market during the forecast period, owing to the rise in prevalence of bone cancer, presence of key players for development of IV ibuprofen medication, and well-established infrastructure in the region. China is expected to register the highest CAGR of 15.2% from 2021 to 2030, owing to increase in the number of hospitals, prevalence of cancer, and high pediatric population base.
The key players operating in the global intravenous (IV) ibuprofen market include, AFT Pharmaceuticals, Cumberland Pharmaceuticals Inc., Dano Health Group, Grifol, Harbin Gloria Pharmaceuticals Co., Ltd, Hyloris Pharmaceuticals SA, Pharma Bavaria International, Recordati, SG pharma, and XGEN.
By Region
United States was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key Benefits For Stakeholders
- The report provides an in-depth analysis of the global intravenous (IV) ibuprofen market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers intravenous (IV) ibuprofen market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global intravenous (IV) ibuprofen market growth.
Intravenous (IV) Ibuprofen Market Report Highlights
| Aspects | Details |
 By Indication |
|
 By Age Group |
|
 By Region |
|
 By Key Market Players |
|
Analyst Review
Intravenous (IV) ibuprofen injection are used for the treatment of mild to severe pain. The indication include pain or inflammatory and fever. The pain or inflammatory segment dominates the market owing to increase in mucoskelatal diseases and inflammatory conditions.
Factors such as increase in prevalence of cancers, such as bone cancer and nerve cancer, rise in number of hospitals, and high pediatric population treatment drive the growth of the market. In addition, high bio-availability of ibuprofen are expected to drive the growth of the intravenous (IV) ibuprofen market.
U.S. is expected to witness the highest growth, in terms of revenue, owing to the rise in prevalence of bone cancer, and the presence of key players for R&D activities in ibuprofen medication, in the region. However, the side effects associated with ibuprofen, such as gastric ulcers and bleeding are expected to hamper the market growth during the forecast period.
The total market value of intravenous (IV) ibuprofen market is $5.34 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of intravenous (IV) ibuprofen Market in 2021 was $5.00 million
The base year for the report is 2020.
Yes, intravenous (IV) ibuprofen companies are profiled in the report
The top companies that hold the market share in intravenous (IV) ibuprofen market are AFT Pharmaceuticals, Cumberland Pharmaceuticals Inc., Dano Health Group, Grifol, Harbin Gloria Pharmaceuticals Co., Ltd, Hyloris Pharmaceuticals SA, Pharma Bavaria International, Recordati, SG pharma, and XGEN.
China is expected to register the highest CAGR of 15.2% from 2021 to 2030, owing to increase in the number of hospitals, prevalence of cancer, and high pediatric population base
The key trends in the intravenous (IV) ibuprofen market are increase in prevalence of bone and muscle disorders, such as ankylosing spondylitis (a rare type of arthritis) and rheumatoid arthritis
Loading Table Of Content...
